This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Beijing University of Technology, Hudson Institute of Medical Research, Monash University. Active years: 2021-2025.
Company Filing History:
1 out of 388 
1 out of 10 
1 out of 18 Years Active: 2021-2025
Title: Andrew Ellisdon: Innovator in Anti-Inflammatory Therapeutics
Introduction
Andrew Ellisdon is a notable inventor based in Clayton, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic polypeptides. His work focuses on innovative solutions for treating inflammatory diseases.
Latest Patents
Andrew Ellisdon holds a patent for IL-37 variants. This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also encompasses the use of these polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, with mutations or modifications to prevent the anti-inflammatory peptide from forming a homodimer. He has 1 patent to his name.
Career Highlights
Throughout his career, Andrew has worked with prestigious institutions, including Beijing University of Technology and the Hudson Institute of Medical Research. His research has contributed to advancements in the understanding and treatment of inflammatory conditions.
Collaborations
Andrew has collaborated with notable colleagues, including Marcel Nold and Claudia Nold. Their combined expertise has furthered research in the field of anti-inflammatory therapeutics.
Conclusion
Andrew Ellisdon's innovative work in the development of IL-37 variants showcases his commitment to advancing medical science. His contributions are paving the way for new therapeutic options in the treatment of inflammatory diseases.